Utility of 2-Hydroxypropyl-β-cyclodextrin in an Intramuscular Injectable Preparation of Nimodipine

Chemical and Pharmaceutical Bulletin

Volumn 38, Issue 1, 1990, Pages 176-179

  Yoshida, Atsuya ^a   Yamamoto, Masanobu ^a   Itoh, Takahiro ^a   Irie, Tetsumi ^a   Hirayama, Fumitoshi ^a   Uekama, Kaneto ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

bioavailability; complexation; hydroxyalkylated cyclodextrin; intramuscular administration; muscular damage; nimodipine; solubilization

Indexed keywords

BETA CYCLODEXTRIN DERIVATIVE; DRUG CARRIER; NIMODIPINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOAVAILABILITY; BLOOD LEVEL; DRUG FORMULATION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; RABBIT;

ANIMAL; CYCLODEXTRINS; DEXTRINS; EXCIPIENTS; INJECTIONS, INTRAMUSCULAR; MALE; NIMODIPINE; RABBITS; SOLUBILITY; STARCH;

EID: 0025236395     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.38.176     Document Type: Article

References (15)

1. 1) R. Towart and E. Perzborn, Eur. J. Pharmacol., 69, 213 (1981). S. Kazda, B. Garthoff, H. P. Krause, and K. Schlossmann, Arzneim.-Forsch./Drug Res., 32, 331 (1982).
2. 3) K. D. Rämsch, K. H. Graefe, D. Scherling, J. Sommer, and R. Ziegler, Am. J. Nephrol., 6, 73 (1986).
3. 4) J. Szejtli, “Cyclodextrins and Their Inclusion Complexes,” Akademiai Kiadó, Budapest, 1982.
4. 5) J. Pitha and J. Pitha, J. Pharm. Sci., 74, 987 (1985).
5. 6) K. Uekama, Pharm. Tech. Japan, 4, 183 (1988).
6. 7) M. Brewster, K. Estes, and N. Bodor, Int. J. Pharm., in press.
7. 8) A. Yoshida, H. Arima, K. Uekama, and J. Pitha, Int. J. Pharm., 46, 217 (1985).
8. 9) A. Yoshida, M. Yamamoto, T. Irie, F. Hirayama, and K. Uekama, Chem. Pharm. Bull., 37, 1059 (1989).
9. 10) T. Higuchi and K. A. Connors, Adv. Anal. Chem. Instr., 4, 117 (1965).
10. 11) M. Tsuruoka, T. Hashimoto, H. Seo, S. Ichimasa, O. Ueno, T. Fujinaga, M. Otagiri, and K. Uekama, Yakugaku Zasshi, 101, 360 (1981).
11. 12) K. Uekama, T. Imai, T. Maeda, T. Irie, F. Hirayama, and M. Otagiri, J. Pharm. Sci., 74, 841 (1985).
12. 13) H. Nogami, T. Nagai, and Y. Yotsuyanagi, Chem. Pharm. Bull., 17, 499 (1969).
13. 14) S. Shintani, M. Yamazaki, M. Nakamura, and I. Nakayama, Toxicol. Appl. Pharmacol., 11, 293 (1967).
14. 15) K. Yamaoka, Y. Tanigawara, T. Nakagawa, and T. Uno, J. Pharmacobio-Dyn., 4, 879 (1981).
15. 16) K. Uekama et al., unpublished data.